A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 ??G/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Lubricin (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Lubris BioPharma
Most Recent Events
- 29 Sep 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Aug 2025 New trial record